NEW YORK (360Dx) – Clinicians need more effective, rapid susceptibility testing of first-line and second-line tuberculosis drugs, especially in clinics located in low- and middle-income countries, according to the authors of a study published recently in The Lancet Infectious Diseases.
Get the full story with
360Dx Premium
Only $95 for the
first 90 days*
360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.